Does first-line treatment with palbociclib prolong life in patients with triple-positive breast cancer?

Zenodo (CERN European Organization for Nuclear Research) 2026 Open access

Read full text
Authors: Tripdatabase
DOI: 10.5281/zenodo.18489436
Cited by: 0

Abstract

Current evidence does not demonstrate a statistically significant improvement in overall survival with palbociclib for triple-positive breast cancer, highlighting a need for further research in this subset.

Fields of Study & Subjects

Advanced Breast Cancer Therapies Breast Cancer Treatment Studies PARP inhibition in cancer therapy

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
4 February 2026